Immune thrombocytopenia in adolescents and young adults

• DOI: 10.3389/fmed.2025.1553936
• Publication Date: 2025-03-26T07:22:07Z
• Authors: Alexandra Schifferli
• Keywords: Cytopenia

Previous guidelines for the treatment of immune thrombocytopenia (ITP) have traditionally focused on a dichotomy between pediatric and adult ITP. Adolescents young adults (AYAs) do not neatly fit into either or ITP group. A deeper understanding ITP’s natural history, risk factors chronicity, outcomes in AYAs is crucial first step toward developing tailored algorithms. Such data could form basis recommendations targeting this underrepresented yet clinically distinct population. Ultimately, age-adapted trials may improve long-term outcomes, reduce toxicity, enhance quality life with The collaboration—drawing from Pediatric Adult Registry Chronic (PARC-ITP), Registre Midi- Pyrénéen-France (CARMEN-France) registry Toulouse, National Prospective Cohort Children Autoimmune Cytopenia (OBS’CEREVANCE) Bordeaux, France—aims to address information gap To date, four analyses been undertaken (using 2004 2021), each addressing major clinical aspects patients aged 12–25 years: (1) newly diagnosed ITP, (2) chronic disease, (3) refractory courses, (4) secondary (sITP) forms.